Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios‐Romenets, Silvia, Lopera, Francisco, Sink, Kaycee M., Hu, Nan, Lian, Qinshu, Guthrie, Heather, Smith, Jillian, Cho, William, Mackey, Howard, Langbaum, Jessica B., Thomas, Ronald G., Giraldo‐Chica, Margarita, Tobon, Carlos, Acosta‐Baena, Natalia, Muñoz, Claudia, Ospina, Paula, Tirado, Victoria, Henao, Eliana, Bocanegra, Yamile, Chen, Kewei, Su, Yi, Goradia, Dhruman, Thiyyagura, Pradeep, VanGilder, Paul S., Luo, Ji, Ghisays, Valentina, Lee, Wendy, Malek‐Ahmadi, Michael H., Protas, Hillary D., Chen, Yinghua, Quiroz, Yakeel T., Reiman, Eric M., Tariot, Pierre N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Featured Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819133/
https://www.ncbi.nlm.nih.gov/pubmed/32418361
http://dx.doi.org/10.1002/alz.12109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819133/
https://www.ncbi.nlm.nih.gov/pubmed/32418361
http://dx.doi.org/10.1002/alz.12109

Ejemplares similares